Deepika Jalota
CIK 1825192 · View on SEC EDGAR ↗
First SEC filing: Sept. 24, 2020 · Latest: Sept. 24, 2020
On this page
- Insider at Companies where this person is a reporting insider.
- Insider transactions Every share this person bought or sold, from Form 4 filings.
- Derivatives Options and other derivative holdings reported by this person.
- Initial holdings The stakes this person held when they first started reporting.
- Compensation Executive pay disclosed in company proxy statements.
Insider at
Insider transactions
Price change vs current quote, split-adjusted for corporate actions since the filing — not benchmarked, not annualized, not size-weighted
| Date | Ticker | Code | Shares | Price | Value | Owned after | Δ own | A/D | vs now |
|---|---|---|---|---|---|---|---|---|---|
| Sept. 11, 2024 | PMVP | S | 7,218 | $1.50 | $10,827 | 118,283 Direct | -5.75% | Disposed | -10.7% (price as of 2026-08-20) |
| Sept. 15, 2023 | PMVP | S | 4,104 | $6.62 | $27,168 | 29,946 Direct | -12.05% | Disposed | -79.8% (price as of 2026-08-20) |
| Aug. 17, 2021 | PMVP | S 10b5-1 | 2,896 | $33.78 | $97,827 | 0 Direct | -100.00% | Disposed | -96.0% (price as of 2026-08-20) |
P = Open-market purchase · S = Sale · A = Grant/award · M = Option exercise · G = Gift · F = Tax withholding
Insider transactions are not a recommendation; sales are often driven by liquidity or tax reasons.
Derivative holdings (Form 4 Table II)
Options, RSUs and convertible securities reported on Form 4 Table II.
| Date | Ticker | Security | Underlying | Exercise price | Expiration | Shares | A/D |
|---|---|---|---|---|---|---|---|
| Aug. 13, 2024 | PMVP | Employee Stock Option (right to buy) | Common Stock (22,674) | $28.33 | May 11, 2031 | 22,674 | Disposed |
| Aug. 13, 2024 | PMVP | Employee Stock Option (right to buy) | Common Stock (68,100) | $16.29 | Feb. 10, 2033 | 68,100 | Disposed |
| Aug. 13, 2024 | PMVP | Employee Stock Option (right to buy) | Common Stock (90,774) | $1.48 | Aug. 13, 2034 | 90,774 | Acquired |
| Aug. 13, 2024 | PMVP | Employee Stock Option (right to buy) | Common Stock (125,000) | $5.70 | May 12, 2033 | 125,000 | Disposed |
| Aug. 13, 2024 | PMVP | Employee Stock Option (right to buy) | Common Stock (125,000) | $1.49 | March 13, 2034 | 125,000 | Acquired |
| Jan. 18, 2024 | PMVP | Employee Stock Option (right to buy) | Common Stock (225,095) | $1.80 | Jan. 18, 2034 | 225,095 | Acquired |
| May 12, 2023 | PMVP | Employee Stock Option (right to buy) | Common Stock (125,000) | $5.70 | May 12, 2033 | 125,000 | Acquired |
| Feb. 10, 2022 | PMVP | Employee Stock Option (right to buy) | Common Stock (68,100) | $16.29 | Feb. 10, 2032 | 68,100 | Acquired |
| Aug. 17, 2021 | PMVP | Stock option (right to buy) | Common Stock (2,896) | $3.53 | Aug. 20, 2029 | 2,896 | Disposed |
| May 12, 2021 | PMVP | Employee Stock Option (right to buy) | Common Stock (22,674) | $28.33 | May 11, 2031 | 22,674 | Acquired |
Exercise/conversion price is blank when not applicable (e.g. RSUs).
Initial ownership (Form 3) 2 holdings
Securities held when first becoming an insider, per SEC Form 3.
Compensation (DEF 14A)
Matched by name from proxy statements (DEF 14A) — verify against the filing.
PMVP
Pharm.D.Chief Development Officer| Fiscal year | Salary | Bonus | Stock awards | Option awards | Non-equity incentive | Pension change | Other | Total |
|---|---|---|---|---|---|---|---|---|
| 2025 | $478,429 | — | — | $282,120 | $174,638 | — | — | $935,187 |
| 2024 | $442,542 | — | $171,999 | $1,118,651 | $195,822 | — | — | $1,929,014 |
| 2023 | $421,898 | — | — | $503,300 | $172,000 | — | — | $1,097,198 |
Figures from the Summary Compensation Table of the company's proxy statement (DEF 14A). Compensation is not a recommendation.